Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.
about
A critical role for the Sp1-binding sites in the transforming growth factor-beta-mediated inhibition of lipoprotein lipase gene expression in macrophagesCD40 in coronary artery disease: a matter of macrophages?The role of platelets in the recruitment of leukocytes during vascular diseaseCD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury.Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis.Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets.Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profileInflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics.CD40L and Its Receptors in Atherothrombosis-An UpdateInflammatory micro-environmental cues of human atherothrombotic arteries confer to vascular smooth muscle cells the capacity to trigger lymphoid neogenesis.Beta3 integrin deficiency promotes atherosclerosis and pulmonary inflammation in high-fat-fed, hyperlipidemic mice.Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice.Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand systemPotential role for immunomodulatory therapy in atherosclerotic plaque stabilisation.Inflammation in coronary artery disease: potential role for immunomodulatory therapy.Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling.Novel Therapy for Atherosclerosis Using Recombinant Immunotoxin Against Folate Receptor β-Expressing MacrophagesFuture innovations in anti-platelet therapies.Autoimmunity in atherosclerosis: a protective response losing control?Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis.Abrogated transforming growth factor beta receptor II (TGFβRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis.TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases.The Role of Immunogenicity in Cardiovascular Disease.Tumor necrosis factor superfamily molecules in acute coronary syndromes.The CD40-CD40L system in cardiovascular disease.Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets.Therapeutic strategies to deplete macrophages in atherosclerotic plaques.Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis.CD40-CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications.Inflammation and immune system interactions in atherosclerosis.CD154: the atherosclerotic risk factor in rheumatoid arthritis?Regulation of atherosclerotic plaque inflammation.Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis.Effect of Smoking on Metalloproteinases (MMPs) Activity in Patients with Acute Myocardial Infarction (AMI).ATVB Distinguished Scientist Award: How Costimulatory and Coinhibitory Pathways Shape Atherosclerosis.Blockade of CD40-TRAF2,3 or CD40-TRAF6 is sufficient to inhibit pro-inflammatory responses in non-haematopoietic cells.Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40+ monocyte differentiation.Antiplatelet therapy: current strategies and future trends.T-cell co-stimulators as anti-inflammatory targets for atherosclerotic disease.
P2860
Q24795518-14DF4F5F-2A2D-480E-8297-86ACA3655DE6Q26752784-83DEF7FA-AE53-4B94-B620-AE6269F36A8DQ26801407-730C10D9-17D7-4802-84EC-791482D3AFC9Q30441065-B07F2FF5-E262-42A2-AD5B-16F181EC7828Q30497499-15BACC1E-578C-48F9-8A18-4ABBBC03D37EQ33183129-8E865978-1F83-444E-BB10-3FE119C53586Q33656103-CC2D51F9-384E-44F6-AA9E-171848AB8691Q33805176-3DDB5F7F-CECF-4CDE-932E-AFA228F0C449Q33814059-DA0CC962-F8E7-4BDB-8448-877D8E61DD0DQ34790656-DDA96FF2-14E0-47CD-B090-C4EEB826C41BQ35144122-8C6495B0-3382-44F3-B01E-FDD409A851E8Q35789286-AD36907D-BA6D-4AB0-8AC5-E978E2CB899DQ35824531-A9E5AF39-5259-482C-B35F-28D67C15E964Q36216095-18A7EF41-0009-4E2B-BD18-8DAA055DFFD7Q36283698-199A2FFC-970C-4AD8-A76B-84D10399BC84Q36314881-72938EFD-7E56-45A8-A2A0-4B29236924C6Q36350146-D0697FF7-690B-44BF-9D36-D796A18FC6EBQ36366225-8A7C200F-A735-4706-A0A7-F419BBD2114EQ36753593-98DF06F5-F522-44F6-BCA3-A00C9B01BFBBQ37138017-3223F2A7-F9F9-4892-902E-0403161B1923Q37300823-281FE52A-6DB0-4BC8-AA8D-CD0819D2F7DAQ37407750-687B20D9-EBCC-4D23-B57B-CAA277DEDD20Q37494039-F531FDEE-6E9C-4337-B9EC-B07766EE6D06Q37560012-FEE48626-FA15-4494-B8E8-FCE33E088672Q37805514-68E63C9D-8656-42B6-8ED6-9C99F39366DEQ37829738-FFC116C5-0074-49F9-96AA-A7F2D01B80F9Q37866627-643AE374-BF11-468F-8F08-945A813AC2AFQ37981725-63F14631-B718-401E-B124-4915D04EB91EQ38016490-69E7BD0A-B769-4215-B212-E83ADB2F6C8FQ38042321-3763D986-9310-464B-A2E1-607B3E849664Q38083555-050D3332-8370-4E1F-BF25-EB2B9D974CACQ38083874-1A2876F5-D205-42EF-B71E-129BAFE4E41BQ38396097-EC9635B0-B2D9-43A3-AFB5-E02D0A251C74Q38406177-B832D932-9231-4740-AAE2-FC50E1E8D210Q38587974-C638B368-7BB6-471A-84A5-5C2DD4F8E394Q38737500-539A02ED-CBEE-4108-A447-09835C24755AQ38972708-E848799A-6718-4A32-8977-6EBB2E62ECB3Q39454807-4AB3CB10-9FB3-4EB8-9C8F-AC329E7B5DB5Q40329892-C3DB3085-1F76-41C2-A69A-EA046903FFC3Q40347857-A5D00B52-501B-43C7-8C2F-4918C88BF81C
P2860
Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.
@ast
Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.
@en
type
label
Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.
@ast
Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.
@en
prefLabel
Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.
@ast
Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.
@en
P2093
P2860
P356
P1476
Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.
@en
P2093
Cleutjens KB
Heeneman S
Koteliansky VE
P2860
P304
P356
10.1073/PNAS.97.13.7464
P407
P577
2000-06-01T00:00:00Z